Administration of insulin-like growth factor-I (IGF-I) or growth hormone (GH) is known to stimulate bone turnover and kidney function. To investigate the effects of IGF-I and GH on markers of bone turnover, eight adult GH-deficient patients (48 Ϯ 14 yr of age) were treated with IGF-I (5 g/kg/h in a continuous sc infusion) and GH (0.03 IU/kg/daily sc injection at 2000 h) in a randomized cross-over study. We monitored baseline values for three consecutive days before initiating the five-day treatment period, as well as the wash-out period of ten weeks. Serum osteocalcin, carboxyterminal and aminoterminal propeptide of type I procollagen (PICP and PINP, respectively) increased significantly within 2-3 days of both treatments (P Ͻ 0.02) and returned to baseline levels within one week after the treatment end. The changes in resorption markers were less marked as compared with formation markers. Total 1,25-dihydroxycholecalciferol (1,25-(OH) 2 D 3 ) rose significantly, whereas PTH and calcium levels remained unchanged during either treatment. Conclusions: Because the rapid increase in markers of bone formation was not preceded by an increase in resorption markers, IGF-I is likely to stimulate bone formation by a direct effect on osteoblasts. Moreover, because PTH, calcium, and phosphate remained unchanged, IGF-I appears to stimulate renal 1␣-hydroxylase activity in vivo. (J Clin Endocrinol Metab 98: 81-87, 1998) 
D
URING the last years growth hormone (GH) and insulin-like growth factor-I (IGF-I) have received increasing attention as possible anabolic agents for the treatment of osteoporosis. IGF-I is known to mediate some of the actions of GH, and it acts in an endocrine and/or paracrine/ autocrine fashion (1) . Both hormones stimulate bone cells in vivo as well as in vitro (2) (3) (4) (5) . GH stimulates longitudinal bone growth but also plays an important role in the remodeling of (especially cortical) bone in the adult (6) . Depending on the time of onset, GH deficiency (GHD) may result in reduced bone mineral content (7) (8) (9) . Treatment with GH of adult GH-deficient patients increases parameters of bone turnover (10 -12) . It remains unclear whether GH acts on bone directly or indirectly via increased synthesis of IGF-I. IGF-I stimulates longitudinal enchondral bone formation and increases type I procollagen messenger RNA (mRNA) levels in bone of hypophysectomized rats in vivo (13, 14) . Effects of IGF-I on bone turnover in GH-deficient patients have not been reported.
Aging is associated with decreasing serum concentrations of GH and IGF-I (15), a decrease in skeletal muscle and bone mass (16, 17) , a decline in creatinine clearance and serum 1,25-(OH) 2 D 3 levels (18, 19) , and with an increase in PTH levels. Some of the actions of GH on the kidney may also be mediated by IGF-I; the latter has been reported to increase glomerular filtration rate and the production of 1,25-(OH) 2 D 3 in healthy humans (20, 21) . However, the role of IGF-I in the regulation of 1,25-(OH) 2 D 3 in GH-deficient patients is not known.
To investigate the effects of IGF-I (and GH) on bone metabolism and on 1,25-(OH) 2 D 3 production, we conducted a cross-over short-term treatment with both peptide hormones in adults with GHD.
Subjects and Methods Subjects
Eight patients (48 Ϯ 14 yr of age, range 25-72 yr, BMI 25.2 Ϯ 3.7 kg/m 2 , 3 men and 5 women) with adult onset of GHD were studied after obtaining written informed consent. GHD was diagnosed by history and by low serum level of IGF-I. All subjects had completed growth and puberty at the time of diagnosis, and all had GH deficiency of at least 2 yr duration. None had previously received GH substitution therapy, and the previous hormone replacement therapy was maintained unchanged. One subject (patient 5) had noninsulin-dependent diabetes mellitus (NIDDM), treated with diet and a sulfonylurea, and a moderate renal insufficiency (creatinine of 150 mol/L). The study protocol had been approved by the ethics committee of the University Hospital of Zü rich. Patient characteristics are shown in Table 1 .
Experimental design (Fig. 1) The study consisted of two periods of five days each, during which the subjects received continuous sc infusion of 5 g/kg/h rhIGF-I or sc injections of GH (0.03 IU/kg/daily at 2000 h) in a crossover, randomized fashion. The patients were instructed not to change their diet or life-style. They were seen as outpatients and remained engaged in their normal daily activities during the study. Body weight and blood pressure were measured and side effects recorded at each clinic visit. Baseline blood chemistries were sampled for three consecutive days before starting treatment, and a wash-out period of ten weeks was also protocolled. After a 10-h overnight fast, blood samples were drawn at 0800 h for determinations of total serum IGF-I, glucose, calcium, albumin, phosphate, creatinine, osteocalcin, carboxyterminal propeptide of type I procollagen (PICP), aminoterminal propeptide of type I procollagen (PINP), PTH, 1,25-(OH) 2 D 3 , and Vitamin D binding protein (DBP). A 2-h fasting urine collection served for the determination of calcium, total and free deoxypyridinoline, phosphate, and creatinine excretion.
Analytical methods
Total serum levels of IGF-I and of 1,25-(OH) 2 D 3 were measured by radioimmunoassay, DBP using radial immunodiffusion, and the free calcitriol index calculated as the molar ratio of the concentrations of total 1,25-(OH) 2 D 3 and DBP as previously described (21) .
Intact PTH and osteocalcin levels in serum were measured using two-site immunoradiometric assays (IRMA, Nichols Institute, San Juan Capistrano, CA).
Serum levels of PICP and PINP were measured with recently developed RIA kits (Orion Diagnostica, Espoo, Finland) (Mellko 1990). The lower detection limit of the tests is 1.2 g/L and 2 g/L, respectively.
Serum calcium, phosphate, albumin, and creatinine were analyzed according to standard laboratory methods. Serum calcium was corrected for individual variations in serum albumin using the formula:
. Plasma glucose was measured as previously described (22) .
Urinary free deoxypyridinoline was measured using a competitive enzyme immunoassay (Pyrilinks-D kit, Metra Biosystems, Inc., Mountain View, CA), and values were expressed relative to creatinine excretion. Urinary total deoxypyridinoline was measured using high performance liquid chromatography. Urinary calcium, phosphate, and creatinine were analyzed according to standard laboratory methods. Fasting urinary calcium excretion (U Ca ), expressed as U Ca V/GFR (mmol/L) ϭ U Ca ϫ P Cr /U Cr was calculated from 2-h fasting urine collections. The ratios of deoxypyridinoline/creatinine (Dpyr/creatinine, nmol/mmol) and calcium/creatinine were also calculated from 2-h fasting urine samples. All samples from each patient were analyzed in a single assay to avoid interassay variation.
Statistics
Results are expressed as mean Ϯ sd. The results were analyzed using the two-tailed Wilcoxon's rank-sum test for paired difference.
A P value of less than 0.05 was considered statistically significant.
Results

Clinical observations
All subjects tolerated the treatments well and completed the study. No episode of hypoglycemia and no significant changes in blood pressure were observed. During the GHtreatment blood glucose increased markedly in patients P2 and P5 (the diabetic patient). A generalized, nonpitting sc edema with a weight gain of 4 kg developed in one patient (P6) during IGF-I treatment, but regressed after the end of the treatment.
Baseline values
Baseline values of serum IGF-I and all other measured parameters were similar at the start of each treatment period (Figs. 2-5 ). Apart from the low IGF-I levels, i.e. 7.5 Ϯ 2.5 
Laboratory values during treatment period
Serum IGF-I. GH treatment led to a less pronounced increase of serum IGF-I levels than IGF-I treatment. Serum IGF-I level rose significantly from 7.5 Ϯ 2.5 to 77 Ϯ 22.3 (IGF-I) (P Ͻ 0.02) and from 7.7 Ϯ 1.2 to 24.1 Ϯ 7.9 nmol/L (GH) (P Ͻ 0.02), respectively (Fig. 2) .
Biochemical markers of bone turnover
The effects of either treatment on biochemical markers of bone formation and resorption are shown in Figures 3  and 4 .
Bone formation. A slight but significant increase in serum osteocalcin levels was observed after three days of each treatment: during IGF-I from 3.9 Ϯ 1.8 to 4.9 Ϯ 2.1 g/L (P Ͻ 0.02) and during GH from 4.1 Ϯ 2.5 to 5.2 Ϯ 3.1 g/L (P Ͻ 0.02). One week after stopping treatment the osteocalcin levels were back to baseline. The type I procollagen fragments, serum PICP and PINP, rose quickly and markedly during IGF-I therapy from 85 Ϯ 27 (baseline) to 135 Ϯ 29 g/L (P Ͻ 0.02), and from 30.6 Ϯ 16.4 (baseline) to 54.7 Ϯ 21.8 g/L (P Ͻ 0.02), respectively, and were back to the baseline two days after treatment end. During GH treatment, PICP levels rose from 86 Ϯ 26 to 113 Ϯ 29 g/L (P Ͻ 0.02) and PINP levels from 31.9 Ϯ 20.1 to 45.2 Ϯ 24.2 g/L, and remained elevated until two days after treatment end.
Bone resorption. The urinary free Dpyr/creatinine ratio increased from 4.3 Ϯ 1.2 (baseline) to 5.8 Ϯ 1.8 nmol/mmol (P Ͻ 0.02) after three days of IGF-I treatment and remained significantly elevated above baseline until one week (P Ͻ 0.02) after the end of treatment, whereas with GH, the maximal level (5.3 Ϯ 1.5 nmol/mmol) was reached one day after stopping treatment, followed by a rapid return to baseline. Urinary total Dpyr/creatinine ratio remained unchanged during both treatment periods. The fasting urinary calcium/ creatinine ratio rose from 0.11 Ϯ 0.06 (baseline) to 0.37 Ϯ 0.27 (IGF-I) (P Ͻ 0.02) and from 0.13 Ϯ 0.09 to 0.26 Ϯ 0.19 mmol/ mmol (GH) (P Ͻ 0.02) after 4 -5 days of treatment, respectively. Likewise, U Ca V/GFR rose from 0.014 Ϯ 0.008 (baseline) to 0.031 Ϯ 0.020 (IGF-I) (P Ͻ 0.02) and from 0.014 Ϯ 0.012 to 0.026 Ϯ 0.021 mmol/L (GH) (P Ͻ 0.03), respectively.
The relative effects of both peptide hormones on bone formation versus resorption are shown in Table 2 .
Serum phosphate, calcium and calcium regulating hormones
Serum phosphate and albumin remained unchanged during both treatments. Total calcium, corrected for albumin, increased slightly but not significantly during both treatments from 2.19 Ϯ 0.08 to 2.25 Ϯ 0.07 mmol/L during IGF-I, and from 2.20 Ϯ 0.07 to 2.23 Ϯ 0.07 mmol/L during GH, respectively. Serum PTH levels remained unchanged during both treatment periods.
A significant increase in serum total 1,25-(OH) 2 D 3 levels was observed after 3 days of IGF-I treatment from 43.2 Ϯ 14.7 to 61.7 Ϯ 29.8 (P Ͻ 0.02) and after 5 days of GH treatment from 45.7 Ϯ 14.7 to 66.2 Ϯ 33.8 pg/ml (P Ͻ 0.04). 24 hours after stopping treatment total 1,25-(OH) 2 D 3 levels were back to the baseline (Fig. 5) . DBP remained unchanged during both treatment periods. Consequently, the free calcitriol index rose from 1.63 Ϯ 0.49 ϫ 10 Ϫ5 to 2.31 Ϯ 0.71 ϫ 10 Ϫ5 (IGF-I) (P Ͻ 0.02) and from 1.70 Ϯ 0.44 ϫ 10 Ϫ5 to 2.28 Ϯ 0.88 ϫ 10
Ϫ5
(P Ͻ 0.03) (GH), respectively.
Kidney function
Serum creatinine levels fell only during IGF-I therapy, from 107.5 Ϯ 28.7 (baseline) to 89.5 Ϯ 22.7 mmol/L (P Ͻ 0.02), whereas there was no significant decrease during GH therapy (103.3 Ϯ 18.7 vs. 98.8 Ϯ 22.0 mol/L) (Fig. 5) . Serum urea levels fell during both treatments, from 6.7 Ϯ 3.4 (baseline) to 4.6 Ϯ 3.0 (IGF-I) (P Ͻ 0.02) and from 5.9 Ϯ 2.0 to 4.5 Ϯ 2.9 mmol/L (GH) (P Ͻ 0.02), respectively.
Discussion
We undertook this study to test whether IGF-I and GH had similar short time effects on bone turnover and on production of 1,25-(OH) 2 D 3 in adults with GHD. On the other hand it is known that IGF-I and GH have opposite effects on carbohydrate and lipid metabolism (22, 23) . Besides mediating some actions of GH on skeletal growth, IGF-I inhibits GH secretion by way of feedback control. GH-deficient patients are of particular interest to study the effects of IGF-I, as the inhibitory effects of IGF-I on GH secretion cannot occur. For the present study, we decided to use a relatively low, supposedly well-tolerated dose of both GH and IGF-I so that the protocol could be carried through without later modification. We found that both peptide hormones stimulate bone formation and resorption as well as the synthesis of 1,25-(OH) 2 D 3 in GH-deficient adults.
Stimulatory effects of GH on bone turnover have been well documented in healthy adult humans (24) and in patients with GHD (10 -12) , and some but not all revealed a beneficial effect of GH treatment on bone mineral content (25) (26) (27) . In patients lacking functional GH receptors (type Laron dwarfs) IGF-I therapy affects longitudinal bone growth (28 -30) . It is evident that GH and IGF-I play an important role in the acquisition of peak bone mass, but the effects of IGF-I on bone metabolism and mineral density in the adult are less clear. IGF-I administration stimulates bone turnover in men with osteoporosis (31), in osteopenic women with anorexia nervosa (32) , and in postmenopausal women (33, 34) . In contrast, no report has been published on the effects of IGF-I treatment on bone turnover of GH-deficient adults. Bone turnover is decreased in GH-deficient adults as assessed by histomorphometry and biochemical markers, and increased by GH treatment (9, 35) . Whether the action of GH on bone results from the hormonal effects of circulating IGF-I, from autocrine/paracrine effects of IGF-I, or from IGF-I-independent GH effects is unknown.
In our study both IGF-I and GH treatment led to a rapid and pronounced stimulation of bone collagen production. We found a significant increase in PICP and PINP levels after three days of hormonal treatment and a return to baseline within one week after the end of treatment. The serum osteocalcin levels were also significantly increased by both hormones after three days, but less markedly as compared with the type I collagen propeptides. In agreement, other studies have found slight (31, 32) or no changes (33, 36) of serum osteocalcin in response to IGF treatment. Interestingly, the percentage increase in formation parameters largely exceeded their effects on resorption markers during both treatment periods, as shown in Table 2 . The trial was designed to monitor not only the different response of bone formation and resorption markers during the treatment, but particularly to control whether activation of bone turnover would be characterized by an osteoclast activation followed by a potentially sustained increase of osteoblast activity. However, the effects of IGF-I on bone formation do not appear to be secondary to an initial increase in bone resorption, as observed in the more common states of increased bone turnover in adults, such as PTH excess or sex steroid withdrawal. Moreover, we observed a quick return of the measured parameters to baseline levels and no further changes during the subsequent weeks, in contrast with the prolonged effects of IGF-I found by Johansson et al. (37) in an osteoporotic patient. The stimulatory effects of IGF-I on bone formation in GH-deficient patients suggest an intrinsic action of this peptide on osteoblasts. In fact, IGF-I has been shown to support proliferation, differentiation, and matrix synthesis in cultures of osteoblast-like cells and bone organ cultures. In vitro, IGF-I is a potent stimulator of the production of type I collagen, the main structural protein of bone (4, 38, 39) . IGF-I was also found to increase procollagen ␣ 1 (I) mRNA expression both in osteoblasts in vitro and in bone in vivo (14, 39, 40) .
Osteoblasts express type I IGF receptors and are responsible for bone formation. By contrast, IGF-I has not been shown to exert a direct effect on the activity of mature osteoclasts. The increase in resorption markers possibly reflects an indirect osteoclast activation mediated by a stimulation of osteoblasts, as shown in vitro (41) .
Both GH and IGF-I increase glomerular filtration rate (20, 42) and production of 1,25-(OH) 2 D 3 in vivo (21, 43, 44) . IGF-I stimulates the production of 1,25-(OH) 2 D 3 by kidney cells in vitro (45) . However, the effects of IGF-I on 1,25-(OH) 2 D 3 production have not been tested in GH-deficient human Levels of PICP and DPyr/Crea in percent after 4 days treatment with IGF-I or GH and 2 days after treatment end vs. baseline levels.
subjects. The results of the present study provide further evidence that IGF-I stimulates the production of 1,25-(OH) 2 D 3 independently of GH. The lack of any concomitant change in PTH, phosphate, and calcium levels, which are important regulators of renal 1␣-hydroxylase is compatible with a direct stimulatory effect of IGF-I on 1␣-hydroxylase. Our findings in GH-deficient patients support the notion that IGF-I mediates the stimulatory effect of GH on 1,25-(OH) 2 D 3 production independently of circulating PTH, as recently suggested (46) . The increased total and free concentrations of 1,25-(OH) 2 D 3 did not significantly change serum calcium and circulating PTH levels. Urinary calcium is known to be more sensitive than serum calcium in detecting actions of increased levels of circulating 1,25-(OH) 2 D 3 . The observed rise in urinary calcium may reflect increased net uptake by the gut and/or increased net efflux from the skeleton. We cannot answer the question why PTH secretion was not decreased despite significant elevation of 1,25-(OH) 2 D 3 and a trend for a rise in serum calcium. Speculatively, GH and IGF-I might downregulate the expression of calcium-sensing receptors or influence the expression of PEX (a phosphateregulating gene with homology to endopeptidases located on the X chromosome) and the activity (or secretion) of its putative substrate, phosphatonin, in target tissues.
The age-related concomitant decline of IGF-I concentrations in serum, human cortical bone (47, 48) , and of renal synthesis of 1,25-(OH) 2 D 3 (18) could contribute to the decrease in cortical bone mass in aged persons of both sexes. Administration of GH or IGF-I increases serum IGF-I and the production of collagen in bone as well as the production of 1,25-(OH) 2 D 3 by the kidneys, indicating that these tissues are (and remain upon aging) responsive to the two hormones. GH and IGF-I may also prevent the senile component of osteoporosis, which appears to result mainly from defective bone formation. Only long-term clinical trials will tell us whether the IGF-I effects on bone metabolism are sustained and lead to an increase in bone mass.
Conclusions: our data demonstrate that IGF-I administration, similarly to GH, stimulates bone metabolism and the production of 1,25-(OH) 2 D 3 in GH-deficient adults. Because the increase in markers of bone formation was not preceded by an increase in resorption markers, IGF-I may exert a direct anabolic effect on bone forming cells in vivo. IGF-I appears also to stimulate renal 1␣-hydroxylase activity directly, as PTH, calcium, and phosphate remained unchanged.
